# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for mo...
Anitra (AMEX:AZTR) reported quarterly losses of $(2.74) per share which missed the analyst consensus estimate of $(0.36) by 661...